 | Up a level |
Viale, G.; Giobbie-Hurder, A.; Gusterson, B. A.; Maiorano, E.; Mastropasqua, M. G.; Sonzogni, A.; Mallon, E.; Colleoni, M.; Castiglione-Gertsch, M.; Regan, M. M.; Price, K. N.; Brown, R. W.; Golouh, R.; Crivellari, D.; Karlsson, P.; Öhlschlegel, C.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S. (2009). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology, 21(2), pp. 245-254. Oxford University Press 10.1093/annonc/mdp317
Ravaioli, A.; Monti, F.; Regan, M. M.; Maffini, F.; Mastropasqua, M. G.; Spataro, V.; Castiglione-Gertsch, Monica; Panzini, I.; Gianni, L.; Goldhirsch, A.; Coates, A.; Price, K. N.; Gusterson, B. A.; Viale, G. (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of oncology, 19(4), pp. 660-668. Oxford University Press 10.1093/annonc/mdm547
